Sr141716a

Manufactured by Cayman Chemical

SR141716A is a synthetic compound used as a research tool. It functions as an antagonist of the cannabinoid CB1 receptor.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Rimonabant (SR141716A) (2 citations)

10 protocols using sr141716a

Endocannabinoid Receptor Modulation in Cell Proliferation

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following were purchased from Cayman (Ann Arbor, MI): 2-AG; the endocannabinoid receptor inhibitors, SR141716A (Rimonabant, CB1 inverse agonist), AM251 (CB1 antagonist) and SR144528 (CB2 inverse agonist); the endocannabinoid receptor activators, CP47497 (CB1 agonist), AM1241 (CB2 agonist), Win- 55–212-2 (CB1 and CB2 agonist) and CP55940 (CB1 and CB2 agonist); the selective and nonselective inhibitors for cyclooxygenase-1 and -2 (COX-1, COX-2), SC-560 (selective for COX-1), CAY10404 (selective for COX- 2), Ibuprofen (nonselective for COX-1 and COX-2); and the selective inhibitors for hydrolases of 2-AG, JZL 184 (selective for enzyme monoacylglycerol lipase, MAGL. Anti-bromodeoxyurine (BrdU) antibody was purchased from Roche Applied Science (Indianapolis, IN). The CellTiter 96 Non-Radioactive Cell proliferation Assay Kit™ was purchased from Promega (Madison, WI). Charcoal/dextran-treated fetal bovine serum (CFBS) was purchased from Hyclone (Logan, UT). DMEM, RPMI-1640, antibiotics (penicillin and streptomycin), and fetal bovine serum (FBS) were purchased from Atlanta Biologicals (Lawrenceville, GA).

Zhang J., Medina-Cleghorn D., Bernal-Mizrachi L., Bracci P.M., Hubbard A., Conde L., Riby J., Nomura D.K, & Skibola C.F. (2016). The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. Oncoscience, 3(1), 31-41.

+ Open protocol

+ Expand

Synthesis and Storage of SCRAs

Check if the same lab product or an alternative is used in the 5 most similar protocols

CP55940, WIN55212‐2, 2‐arachidonoylglycerol (2‐AG), CUMYL‐4CN‐BINACA, and SR141716A were purchased from Cayman Chemical, THC was from THC Pharm GmbH and was a kind gift from the Lambert Initiative for Cannabis Therapeutics (University of Sydney). PTX was from HelloBio, and FSK was from Ascent Scientific Ltd. All the SCRAs, unless otherwise stated, were synthesized by Dr Samuel D. Banister in the lab of Professor Michael Kassiou at Sydney University. Chemical structure of SCRAs can be found elsewhere.12 All the SCRAs were prepared in DMSO and stored in aliquots of 30 mmol L⁻¹ in −30°C until needed.

Sachdev S., Banister S.D., Santiago M., Bladen C., Kassiou M, & Connor M. (2020). Differential activation of G protein‐mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research & Perspectives, 8(2), e00566.

+ Open protocol

+ Expand

Cannabinoid Receptor Antagonist Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols

The Cnr1 antagonist, SR141716A (Cayman Chemical 9000484), was dissolved in a vehicle of 2.5% DMSO/0.1% Tween-80 in saline and administered at a dose of 3 mg/kg. SR141716A was administered intraperitoneally (IP) 20 minutes prior to testing on an elevated plus maze.

Bowers M.E, & Ressler K.J. (2015). Sex-dependence of anxiety-like behavior in cannabinoid receptor 1 (Cnr1) knockout mice. Behavioural brain research, 300, 65-69.

+ Open protocol

+ Expand

Cannabinoid Receptor Antagonist Administration

Check if the same lab product or an alternative is used in the 5 most similar protocols

SP600125 was obtained from Sigma (St. Louis, MO). Δ⁹-THC was obtained from the National Institute on Drug Abuse Drug Supply (Baltimore, MD). (−)-CP55,940 (referred in the text as CP55,940), WIN55,212-2, SR141716A (referred in the text as SR1), and SR144528 (referred in the text as SR2) were obtained from Cayman Chemical (Ann Arbor, MI). Δ⁹-THC, CP55,940, SR141716A, and SR144528 were dissolved in 5% ethanol and WIN55,212-2 and SP600125 in 4% DMSO. All drugs were then diluted in a 0.9% physiological saline and 5% Cremaphor EL (18:1 v/v) vehicle and prepared fresh on the day of the experiment prior to being administered intraperitoneally (IP) in an injection volume of 10 ml/kg.

Henderson-Redmond A.N., Nealon C.M., Davis B.J., Yuill M.B., Sepulveda D.E., Blanton H.L., Piscura M.K., Zee M.L., Haskins C.P., Marcus D.J., Mackie K., Guindon J, & Morgan D.J. (2019). c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner. Neuropharmacology, 164, 107847.

+ Open protocol

+ Expand

Preparation and Storage of Cannabinoid Ligands

Check if the same lab product or an alternative is used in the 5 most similar protocols

Forskolin (FSK, F), CP55940, 2‐arachidonoyl glycerol (2‐AG), NESS‐0327, and SR141716A were purchased from Cayman Chemical Company; AM4113 was purchased both from Cayman Chemical Company and Sigma Aldrich.
FSK, and EG‐018 and all analogues were constituted at 31.6 mM in dimethyl sulfoxide (DMSO, Sigma Aldrich); NESS‐0327, AM4113 and SR141716A were constituted at 10 mM in DMSO. FSK was stored in large aliquots at room temperature and reused for multiple experiments, while all other drugs were aliquoted for single use in 0.2 ml tubes and stored at −80°C until use. Vehicle (DMSO and ethanol) content was controlled within each experiment, at 0.1% for each agonist in either DMSO or ethanol, with an additional 0.015% DMSO (for FSK) and an additional 0.1% ethanol for coelenterazine H in cAMP assays (see below).

Finlay D.B., Nguyen T., Gamage T.F., Chen S., Barrus D.G., Patel P.R., Thomas B.F., Wiley J.L., Zhang Y, & Glass M. (2022). Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018. Pharmacology Research & Perspectives, 10(1), e00901.

+ Open protocol

+ Expand

Cannabinoid Receptor Antagonist Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols

SR141716a (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide) (Cayman Chemicals, Ann Arbor, MI) was dissolved in one drop of Tween 80 and then diluted in saline solution. SR141716a or vehicle alone was administered in a 3mg/kg intraperitoneal injection 30 min before the self-administration session.

Robinson S.L, & McCool B.A. (2015). Microstructural Analysis of Rat Ethanol and Water Drinking Patterns Using a Modified Operant Self-administration Model. Physiology & behavior, 149, 119-130.

+ Open protocol

+ Expand

Cannabinoid Receptor Binding Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Compounds were purchased from Sigma-Aldrich (Oakville, ON), with the exceptions of ∆⁹-THC, which was purchased from Toronto Research Chemicals (Toronto, ON) and SR141716A, which was purchased from Cayman Chemicals (Ann Arbor, MI). [³H]CP55,940 (174.6 Ci/mmol) was obtained from PerkinElmer (Guelph, ON). All reagents were obtained from Sigma-Aldrich unless specifically noted. Compounds were dissolved in DMSO (final concentration of 0.1% in assay media for all assays) and added directly to the media at the concentrations and times indicated. For all experiments, 0.1% DMSO was used as the vehicle control.

Zagzoog A., Cabecinha A., Abramovici H, & Laprairie R.B. (2022). Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules. Frontiers in Pharmacology, 13, 956030.

+ Open protocol

+ Expand

THC and Rimonabant Solubilization

Check if the same lab product or an alternative is used in the 5 most similar protocols

THC was provided by the National Institute on Drug Abuse (Bethesda, MD) dissolved in 95% ethanol at a concentration of 100 mg/ml. SR141716A (Rimonabant) was purchased from Cayman Chemical (Ann Arbor, MI) and dissolved in 100% ethanol at a concentration of 20 mg/ml. The SR141716A-ethanol solution was mixed in a vehicle of Tween-20 and saline in a ratio of 1:1:18. The control vehicle contained an equal amount of ethanol without SR141716A.

Smoker M.P., Mackie K., Lapish C.C, & Boehm SL I.I. (2019). Self-Administration of Edible Δ9-Tetrahydrocannabinol and Associated Behavioral Effects in Mice.. Drug and alcohol dependence, 199, 106-115.

+ Open protocol

+ Expand

Cannabinoid Receptor Agonist Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Stock solutions of SR141716a, WIN 55,212-2, AM251, and URB597 (Cayman Chemicals, Ann Arbor, Michigan) were dissolved in 1ml DMSO (Sigma-Aldrich, St. Louis, MO). Final concentrations of DMSO in the perfusate were equal to or less than 0.05%. To facilitate dissolution, one drop tween 80 (Sigma-Aldrich, St. Louis, MO) was added to all stock solutions save URB597 as per the manufacturer’s instructions. Stock solutions were aliquoted and stored at −20°C until use.

Robinson S.L., Alexander N.J., Bluett R.J., Patel S, & McCool B.A. (2015). Acute and Chronic Ethanol Exposure Differentially Regulate CB1 Receptor Function at Glutamatergic Synapses in the Rat Basolateral Amygdala. Neuropharmacology, 108, 474-484.

+ Open protocol

+ Expand

In Vivo Administration of Pharmacological Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols

The pharmacological agents were administered at the following concentrations in vivo: recombinant human IL-1β (Prospec-Tany Techno Gene), 0.3, 1, 3, and 10 ng in 1 μl, i.c.v.51 (link)52 (link); recombinant human IL1Ra (IL1R antagonist, Prospec-Tany Techno Gene), 2, 20, 50, and 100 ng in 1 μl, i.c.v.52 (link); SR 141716 A (CB1R antagonist, Cayman Chemical), 1 and 10 mg/kg, i.p.53 (link); WIN 55,212-2 (CB1R agonist, Cayman Chemical), 0.5 mg/kg, i.p.54 (link); RHC 80267 (inhibitor of diacylglycerol lipase, Sigma), 1 mg in 2 μl, i.c.v.55 (link); KA (Sigma), 0.5 μg/μl, i.c.v. The solvent of SR 141716 A and WIN 55,212-2 was 80% saline +10% ethanol +10% Tween 20.

Feng B., Tang Y., Chen B., Xu C., Wang Y., Dai Y., Wu D., Zhu J., Wang S., Zhou Y., Shi L., Hu W., Zhang X, & Chen Z. (2016). Transient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling. Scientific Reports, 6, 21931.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!